Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 3/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11607749 | 0.89 | LMNA (0.33) | CHRM2CHRM1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL12367102 | 0.79 | CHRM2 (0.35) | CHRM2CHRM1CHRM4CHRM3TSHR | |
| SCHEMBL21339599 | 0.79 | CHRM2 (0.42) | CHRM2CHRM1CHRM4CHRM3TSHR | |
| SCHEMBL7912591 | 0.79 | CHRM2 (0.42) | CHRM2CHRM1CHRM4CHRM3TSHR | |
| SCHEMBL20229519 | 0.78 | CHRM2 (0.34) | CHRM2CHRM1CHRM4CHRM3TSHR | |
| SCHEMBL10385442 | 0.75 | LMNA (0.42) | CHRM2CHRM1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL13497230 | 0.74 | CHRM2 (0.41) | CHRM2CHRM1CHRM4CHRM3TSHR | |
| SCHEMBL9248112 | 0.74 | — | — | |
| SCHEMBL919567 | 0.73 | — | — | |
| SCHEMBL2739848 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472232-B1 | PROCESSES FOR PREPARING IMIDAZOLE DERIVATIVES AND SALTS THEREOF | YUHAN CORP (KR) | 2007-01-24 | — | — | EP | disclosed |
| EP-1472232-A4 | PROCESSES FOR PREPARING IMIDAZOLE DERIVATIVES AND SALTS THEREOF | YUHAN CORP (KR) | 2006-02-01 | — | — | EP | disclosed |
| EP-1472232-A1 | PROCESSES FOR PREPARING IMIDAZOLE DERIVATIVES AND SALTS THEREOF | Yuhan Corporation (KR) | 2004-11-03 | — | — | EP | disclosed |
| US-6706888-B2 | REACTING A 3-HALOTETRAHYDROFURAN OR TETRAHYDROPYRAN COMPOUND WITH FORMAMIDINE OR ITS SALT IN THE PRESENCE OF A BASE TO PRODUCE A 3-(1H-IMIDAZOL-4-YL)PROPANOL DERIVATIVE; EFFICIENCY; INTERMEDIATES; ANTICARCINOGENIC AGENTS; VIRICIDES; | YUHAN CORPORATION (KR) | 2004-03-16 | — | — | US | disclosed |
| US-20030153769-A1 | Processes for preparing imidazole derivatives and salts thereof | YUHAN CORPORATION | 2003-08-14 | — | — | US | disclosed |
| WO-2003066600-A1 | PROCESSES FOR PREPARING IMIDAZOLE DERIVATIVES AND SALTS THEREOF | YUHAN CORPORATION (KR) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153769-A1 | Processes for preparing imidazole derivatives and salts thereof | NISCH, INF2, SRI | CHRM2 4314/4885CHRM1 3901/4885CHRM4 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.